Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 13/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779830 | 1.00 | AKT2 (0.52) | AKT2GSK3BAKT1NUDT1PBK | |
| SCHEMBL4725770 | 0.82 | AKT1 (0.43) | AKT1ROCK2 | |
| SCHEMBL4918210 | 0.82 | AKT1 (0.43) | AKT1ROCK2 | |
| SCHEMBL4920000 | 0.80 | AKT2 (0.69) | AKT2GSK3BAKT1PBKCYP2C9 | |
| SCHEMBL4919196 | 0.78 | AKT2 (0.61) | AKT2GSK3BAKT1NUDT1PBK | |
| SCHEMBL4727707 | 0.77 | AKT2 (0.52) | AKT2GSK3BAKT1NUDT1PBK | |
| SCHEMBL12547303 | 0.69 | AKT2 (0.52) | AKT2GSK3BAKT1NUDT1PBK | |
| SCHEMBL1000908 | 0.68 | AKT2 (1.00) | AKT2GSK3BAKT1ROCK2CYP2C9 | |
| SCHEMBL1002759 | 0.68 | AKT2 (1.00) | AKT2GSK3BAKT1PBKMETTL3 | |
| SCHEMBL4780249 | 0.68 | ROCK2 (0.42) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT2 1098/4885GSK3B 1722/4885AKT1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.